- Home
- VCNX
VCNX
Vaccinex Inc.
as 12-18-2024 12:44pm EST
Vaccinex Inc is pioneering a differentiated approach to treating cancer and slowly progressive neurodegenerative diseases through the inhibition of semaphorin 4D (SEMA4D). The company's lead drug candidate, pepinemab, blocks SEMA4D, a potent biological effector that it believes prevents immune infiltration into tumors and triggers inflammation in chronic diseases of the brain. Pepinemab is being evaluated in a Phase 1b/2 study in recurrent or metastatic head and neck cancer and in a Phase 1/2a study in Alzheimer's Disease, with ongoing exploration of potential Phase 3 development in Huntington's disease. The firm has also developed a proprietary drug discovery platform, ActivMAb.
| Founded: | 2001 | Country: | United States |
| Employees: | N/A | City: | ROCHESTER |
| Market Cap: | 10.5M | IPO Year: | N/A |
| Target Price: | N/A | AVG Volume (30 days): | 96.1K |
| Analyst Decision: | N/A | Number of Analysts: | N/A |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -12.02 | EPS Growth: | N/A |
| 52 Week Low/High: | $1.25 - $13.02 | Next Earning Date: | 11-14-2024 |
| Revenue: | $388,000 | Revenue Growth: | -51.19% |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Latest Vaccinex Inc. News
VCNX Breaking Stock News: Dive into VCNX Ticker-Specific Updates for Smart Investing
MT Newswires
a day ago
Top Midday Decliners
GuruFocus.com
a day ago
Vaccinex Faces Nasdaq Delisting Amid Financial Struggles; Shares Drop 62%
MT Newswires
a day ago
Vaccinex Stock to Be Delisted From Nasdaq
GlobeNewswire
a day ago
Vaccinex Announces Receipt of Delisting Notification from Nasdaq
GlobeNewswire
a month ago
Vaccinex Reports Third Quarter 2024 Financial Results and Provides Corporate Update
GlobeNewswire
a month ago
Vaccinex Provides Update on ActivMAb® Platform: Multiple Project Deals and Presentation at SITC
GlobeNewswire
a month ago
Vaccinex Reports Improved Immunity Correlating with Clinical Benefit of Pepinemab Combination Treatment at Society for Immunotherapy of Cancer’s Annual Meeting
GlobeNewswire
2 months ago
Vaccinex Reports New Findings for SIGNAL-AD Phase 1b/2 Trial of Pepinemab at Clinical Trials on Alzheimer’s Disease (CTAD) Conference in Madrid, Spain
Compare VCNX vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "VCNX Vaccinex Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.